2012 annual financial data
Regeneron Pharmaceuticals 2012 Operating margin
Direct answer
Operating margin was 33.2%.
Operating income was 457,713,000 USD and net income was 750,269,000 USD.
Operating cash flow was -74,615,000 USD.
Get free Regeneron Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,378,477,000 USD
- Operating income
- 457,713,000 USD
- Net income
- 750,269,000 USD
- Operating cash flow
- -74,615,000 USD